questionText: To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 18 June 2025 to Question 54542 on Drug Prices, how many of the commercial arrangements involving indications-specific pricing were for indications for (a) rare and (b) ult
answerText: Between January 2020 and March 2025, NHS England entered into 62 commercial agreements involving indication-specific pricing for cancer indications. Of these:60 were for indications classified as rare; andof those 60, two were for indications classified a...
heading: Drugs: Prices